| SITE |
SPONSOR |
LOCAL # |
LOCATION(S) OPEN |
STUDY TITLE |
| Any |
NRG |
ARST1321 |
SMH |
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613) |
| Brain |
RTOG |
1071 |
SMH |
RTOG1071/N0577(CODEL): Phase III Intergroup Study of Radiotherapy with
Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma |
| |
RTOG |
3503 |
SMH |
RTOG 3503 Phase II Trial of Optune® Plus Bevacizumab in Bevacizumab-
Refractory Recurrent Glioblastoma |
| |
PI |
70001 |
SMH |
A prospective pilot study of cognitive changes in patients receiving partial
brain radiation: development of a radiation dose-toxicity model for
neuroanatomic targets |
| |
Alliance |
A221101 |
SMH |
A221101: A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) to Reduce Cancer-Related Fatigue in Patients with
High Grade Glioma |
| |
NRG |
NRG-BN003 |
SMH |
NRG-BN003 Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma |
| Breast |
RTOG |
1304 |
Pluta |
NSABP 51_RTOG 1304: A Randomized Phase III Clinical Trial Evaluating
Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary |
| Gastrointestinal |
RTOG |
848 |
SMH, HH |
RTOG 848: A Phase III Trial of Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma |
| |
RTOG |
1112 |
SMH |
RTOG 1112: Phase III Study of Sorafenib versus stereotactic body radiation therapy followed by sorafenib in hepatocellular carcinoma |
| |
NRG |
GI001 |
SMH |
NRG GI001 Randomized Phase III Study Of Focal Radiation Therapy For
Unresectable, Localized Intrahepatic Cholangiocarcinoma |
| |
PI |
ULAB11068 |
SMH |
Analysis of Clinical Data and Lung Dose Using Volumetric Analysis in Patients Treated with Yttrium-90 Microsphere Radioembolization for Hepatocellular Carcinoma |
| |
PI |
UGIP14107 |
SMH, HH |
Pilot Study of Short-Course Preoperative Stereotactic Body Radiation Therapy for Resectable Pancreatic Cancer |
| Genitourinary |
NRG |
0924 |
SMH, HH |
RTOG 0924: Androgen Deprivation Therapy and High Dose Radiotherapy
With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High-Risk Prostate Cancer: A Phase III Randomized Trial |
| |
Industry |
56021927PCR 3003 |
SMH, HH |
Janssen: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of
JNJ-56021927 (ARN-509) in Subjects with High-risk, Localized or Locally
Advanced Prostate Cancer Receiving Treatment with Primary Radiation
Therapy |
| |
DOD |
59133 |
SMH |
Risk Prediction for Development of Adverse Effects Following Radiotherapy
for Prostate Cancer |
| |
NRG |
GU002 |
SMH, HH |
NRG-GU002 Phase II-III Trial of Adjuvant Radiotherapy and Androgen
Deprivation Following Radical Prostatectomy With or Without Adjuvant
Docetaxel |
| Head and Neck |
RTOG |
920 |
SMH, Sands |
A Phase III Study of Postop RT (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer |
| |
RTOG |
1008 |
SMH, HH |
A Randomized Phase II Study of Adjuvant Concurrent Radiation and
Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant
Salivary Gland Tumors |
| |
NRG |
HN001 |
SMH |
NRG HN001: Randomized Phase II and Phase III Studies of Individualized
Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) |
| Lung |
RTOG |
538 |
SMH, HH |
RTOG 538/(CALGB 30610): Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Stage Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide |
| |
Alliance |
A081105 |
SMH |
A081105 ALCHEMIST EGFR + Randomized Study of Erlotinib vs
Observation in Patients with Completely Resected Epidermal Growth Factor
Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) |
| |
Alliance |
A151216 |
SMH, HH, PR, Sands |
ALCHEMIST Screening A151216 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
| |
ECOG |
E4512 |
SMH |
ALCHEMIST ALK+ A Phase III Trial for Surgically Resected Early Stage Non-
Small Cell Lung Cancer: Crizotinib versus Observation for Patients with
Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein |
| |
ECOG |
EA5142 |
SMH |
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized
Phase III Study of Nivolumab After Surgical Resection and Adjuvant
Chemotherapy in Non-Small Cell Lung Cancers |
| |
NRG |
LU002 |
SMH |
NRG LU002: Maintenance Systemic Therapy versus Consolidative
Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic
Therapy For Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A
Randomized Phase II/III trial. |
| Metastases from Breast |
NRG |
BR002 |
SMH |
BR002: A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer |
| Metastases to Brain |
RTOG |
1119 |
SMH |
RTOG 1119: Phase II Randomized Study of Whole Brain Radiotherapy in Combination with Concurrent Lapatinib in Patients with Brain Metastases from HER2-positive Breast Cancer |
| Metastases to Multiple Organs |
NRG |
BR001 |
SMH |
BR001: A Phase I Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases |